Ping Li
Impact in
- Cancer Research top 1%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Cells and Metastasis
Papers in
-
- Gastric Cancer Management and Outcomes 65
- Ferroptosis and cancer prognosis 13
- Oncology 83
- Inflammatory Biomarkers in Disease Prognosis 19
- Cancer Immunotherapy and Biomarkers 13
- Co-authors
- Chang‐Ming Huang (131 shared papers)Chao‐Hui Zheng (115 shared papers)Jian‐Wei Xie (114 shared papers)Jian‐Xian Lin (94 shared papers)Qi‐Yue Chen (96 shared papers)Long‐Long Cao (81 shared papers)Mi Lin (78 shared papers)Jia-Bin Wang (78 shared papers)
- Journals
- European Journal of Surgical Oncology (17 papers)Annals of Surgical Oncology (14 papers)Journal of Cancer (11 papers)Oncotarget (10 papers)BMC Cancer (9 papers)
- Partner nations
- ChinaUnited StatesItaly
In The Last Decade
Ping Li
282 papers receiving 5.7k citations
Ping Li's Hit Papers
Peers
Comparison fields: 5 of 134
- Cancer Research 1.0k
- Oncology 1.6k
- Pulmonary and Respiratory Medicine 1.4k
- Otorhinolaryngology 142
- Gastroenterology 152
Countries citing papers authored by Ping Li
This map shows the geographic impact of Ping Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ping Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ping Li more than expected).
Fields of papers citing papers by Ping Li
This network shows the impact of papers produced by Ping Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ping Li. The network helps show where Ping Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Ping Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 288 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials Hit paper breakdown → | 2018 | 341 |
| 2 | 2020 | 220 | |
| 3 | 2019 | 208 | |
| 4 | 2006 | 164 | |
| 5 | 2018 | 132 | |
| 6 | 2002 | 116 | |
| 7 | 2014 | 104 | |
| 8 | 2020 | 84 | |
| 9 | 2003 | 84 | |
| 10 | 2019 | 82 | |
| 11 | 2020 | 79 | |
| 12 | 2018 | 68 | |
| 13 | 2008 | 62 | |
| 14 | 2004 | 60 | |
| 15 | 2019 | 59 | |
| 16 | 2021 | 59 | |
| 17 | 2018 | 59 | |
| 18 | 2016 | 59 | |
| 19 | 2013 | 57 | |
| 20 | 2017 | 56 |
About Ping Li
Ping Li is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Surgery, having authored 288 papers that have together received 5.8k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (65 papers), RNA modifications and cancer (21 papers), Circular RNAs in diseases (20 papers), Inflammatory Biomarkers in Disease Prognosis (19 papers), MicroRNA in disease regulation (17 papers), Cancer-related molecular mechanisms research (16 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Ferroptosis and cancer prognosis (13 papers). The work is most often cited by research in Cancer Research (1.0k citations), Oncology (1.6k citations), Pulmonary and Respiratory Medicine (1.4k citations), Otorhinolaryngology (142 citations) and Gastroenterology (152 citations). Ping Li has collaborated with scholars based in China, United States and Italy. Frequent co-authors include Chang‐Ming Huang, Chao‐Hui Zheng, Jian‐Wei Xie, Jian‐Xian Lin, Qi‐Yue Chen, Long‐Long Cao, Mi Lin, Jia-Bin Wang, Ru‐Hong Tu and Jun Lü. Their work appears in journals such as European Journal of Surgical Oncology, Annals of Surgical Oncology, Journal of Cancer, Oncotarget and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.